Get App

Valneva makes US regulatory submission for one-shot chikungunya vaccine

Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe in the second half of 2023.
  • Updated On Dec 23, 2022 at 01:29 PM IST
Paris: Vaccines company Valneva said on Friday that it had completed a regulatory submission step with the United States Food & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.

Chikungunya is a mosquito-borne viral disease. Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe in the second half of 2023.
  • Published On Dec 23, 2022 at 01:12 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App